High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy

doi:10.1093/infdis/jiaa256

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24883

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24883

Title:	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy
Authors:	Chang, WY;Chiu, YC;Chiu, FW;Hsu, YC;Tseng, TC;Cheng, PN;Yang, SS;Liu, CJ;Su, TH;Yang, HC;Liu, CH;Chen, PJ;Chen, DS;Kao, JH
Keywords:	Chronic hepatitis B;prophylaxis;entecavir;tenofovir;hematological cancer;hepatic failure;liver decompensation
Date:	2020
Issue Date:	2022-08-09T08:09:33Z (UTC)
Publisher:	OXFORD UNIV PRESS INC
ISSN:	0022-1899
Abstract:	Background: Prophylaxis with nucleos(t)ide analogue (NA) is recommended to prevent hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-positive patients receiving rituximab-based B-cell depletion therapy. However, little is known about the risk of clinical relapse after withdrawal of NA. Methods: We retrospectively analyzed 77 noncirrhotic HBsAg carriers with hematological cancer who received rituximab-containing chemotherapy. All of them received either prophylactic entecavir or tenofovir therapy. The risk of clinical relapse and hepatic decompensation after cessation of NA was explored. Results: Clinical relapse and hepatic decompensation developed in 25 (32.5 %) and 11 (14.3 %) of the patients, respectively, and 2 patients died of hepatic decompensation. Most of the hepatic events occurred within 1 year (20 of 25; 80.0%) after stopping NA. A higher pretreatment viral load (>= 2000 vs <2000 IU/mL) was associated with increased risks of clinical relapse (hazard ratio, 3.47; 95% confidence interval, 1.56-7.73) and hepatic decompensation (9.91; 2.14-45.92). Of 51 patients with pretreatment viral load <2000 IU/mL, clinical relapse occurred in 10 (19.6 %) and hepatic decompensation in 2 (3.9%). Conclusions: Pretreatment HBV DNA >= 2000 IU/mL is associated with increased risk of liver-related disease after cessation of prophylactic NA therapy in patients who received rituximab-containing chemotherapy.
URI:	http://dx.doi.org/10.1093/infdis/jiaa256 https://www.webofscience.com/wos/woscc/full-record/WOS:000577175900016 https://ir.csmu.edu.tw:8080/handle/310902500/24883
Relation:	JOURNAL OF INFECTIOUS DISEASES ,2020 ,v222 ,issue 8 ,p1345-1352
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	152	View/Open

Loading...